Takeda reports additional data from Nesina CV outcomes trial

Share this article:

Takeda has released new data from its cardiovascular safety outcomes trial—EXAMINE—for DPP-4 inhibitor and diabetes treatment Nesina (alogliptin). The study investigated alogliptin's effect on rates of cardiovascular mortality and hospitalization for heart failure in patients with recent acute coronary syndrome.

The company said that its drug “demonstrated no effect on rates of CV mortality,” compared to placebo, and “there was also no increase in sudden cardiac death with alogliptin.”

The trial's principal investigator and abstract author, William B. White, MD, said in a statement, "Cardiovascular events are very common in patients with Type 2 diabetes, so it is important that diabetes treatments adequately manage glucose levels in these patients without adversely affecting cardiovascular outcomes, such as hospitalized heart failure and cardiac death. Based on data presented, alogliptin showed no difference from placebo on rates of cardiovascular mortality and hospitalized heart failure in this high-risk population of patients with Type 2 diabetes." 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.